Basit öğe kaydını göster

dc.contributor.authorCanbek, Umut
dc.contributor.authorAkgun, Ulas
dc.contributor.authorSoylemez, Deniz
dc.contributor.authorCanbek, Tugba Dubektas
dc.contributor.authorAydogan, Nevres Hurriyet
dc.date.accessioned2020-11-20T14:41:11Z
dc.date.available2020-11-20T14:41:11Z
dc.date.issued2019
dc.identifier.issn1022-5536
dc.identifier.issn2309-4990
dc.identifier.urihttps://doi.org/10.1177/2309499019875262
dc.identifier.urihttps://hdl.handle.net/20.500.12809/884
dc.descriptionAkgun, Ulas/0000-0002-5298-6559en_US
dc.descriptionWOS: 000487505100001en_US
dc.descriptionPubMed ID: 31547771en_US
dc.description.abstractPurpose: This study aimed to determine the prevalence of incomplete atypical femoral fractures (iAFFs) in postmenopausal women using bisphosphonates and to investigate the potential risk factors for the development of iAFF. Methods: The national health-care records system indicated that 2746 postmenopausal women in our region aged >= 50 years were taking bisphosphonates. Using an assumed iAFF prevalence of 10% and levels of 5% alpha significance and +/- 5% precision, we calculated that a sample size of 132 participants was needed for this study. The patients were randomly selected and invited to the hospital. Radiographs and bone scans were used to evaluate each patient for iAFF. Bone mineral density, 25-hydroxy vitamin D, parathyroid hormone, and alkaline phosphatase measurements were performed. Results: The mean age of the study population was 72.79 +/- 7.35 years, and the mean duration of bisphosphonate use was 7.7 +/- 3.4 years. We found iAFF in 14 (10.6%) patients, and 3 patients had bilateral involvement. Of the 17 femurs with iAFF, a proximal third location was seen in 2 patients (11.8%), a mid-third location in 14 (82.4%), and a distal third location in 1 (5.9%). The duration of bisphosphonate use was longer, and parathyroid hormone levels were higher in patients with iAFF compared to those without an incomplete fracture. Conclusion: We found a relatively higher prevalence of iAFF in postmenopausal women using bisphosphonate. Early identification and treatment of iAFF is crucial for reducing potential patient morbidity and hospital costs.en_US
dc.item-language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtypicalen_US
dc.subjectBisphosphonateen_US
dc.subjectFemoral Fractureen_US
dc.subjectIncompleteen_US
dc.titleIncomplete atypical femoral fractures after bisphosphonate use in postmenopausal womenen_US
dc.item-typearticleen_US
dc.contributor.departmenten_US
dc.contributor.departmentTemp[Canbek, Umut; Akgun, Ulas; Aydogan, Nevres Hurriyet] Mugla Sitki Kocman Univ, Fac Med, Dept Orthopaed & Traumatol, Mugla, Turkey -- [Soylemez, Deniz] Mugla Sitki Kocman Univ, Dept Nucl Med, Training & Res Hosp, Mugla, Turkey -- [Canbek, Tugba Dubektas] Mugla Sitki Kocman Univ, Dept Internal Med, Training & Res Hosp, Mugla, Turkeyen_US
dc.identifier.doi10.1177/2309499019875262
dc.identifier.volume27en_US
dc.identifier.issue3en_US
dc.relation.journalJournal of Orthopaedic Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster